Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression

Gene

Volumn 562, Issue 1, 2015, Pages 138-144

  Yang, Guanghai ^a   Yang, Lin ^a   Wang, Wendong ^a   Wang, Jiashun ^a   Wang, Jianjun ^a   Xu, Zhongping ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Idiopathic pulmonary fibrosis; MicroRNA; Serum

Indexed keywords

CARBON MONOXIDE; CYTOKINE; CYTOKINE RECEPTOR; JANUS KINASE; MICRORNA; MICRORNA 10A; MICRORNA 125B; MICRORNA 152; MICRORNA 155; MICRORNA 15A; MICRORNA 181A; MICRORNA 199A 5P; MICRORNA 200B; MICRORNA 200C; MICRORNA 218; MICRORNA 25; MICRORNA 28 3P; MICRORNA 301; MICRORNA 31; MICRORNA 454; MICRORNA 885 5P; MICRORNA 9; MICRORNA 98; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; BIOLOGICAL MARKER; MIRN199 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN;

ACTIN FILAMENT; ADULT; ARTICLE; BIOINFORMATICS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOWN REGULATION; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; GENE EXPRESSION PROFILING; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; UPREGULATION; WNT SIGNALING PATHWAY; AGED; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; METABOLIC NETWORKS AND PATHWAYS; MICRORNAS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 84925086698     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.02.065     Document Type: Article

References (41)

1. Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G., Markin C., Lawson W.E., Xie M., Vulto I., Phillips J.A., Lansdorp P.M., Greider C.W., Loyd J.E. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007, 356:1317-1326.
2. Boon K., Bailey N.W., Yang J., Steel M.P., Groshong S., Kervitsky D., Brown K.K., Schwarz M.I., Schwartz D.A. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009, 4:e5134.
3. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Zhang Y., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Wang J., Zen K., Zhang J., Zhang C.Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
4. Cushing L., Kuang P.P., Qian J., Shao F., Wu J., Little F., Thannickal V.J., Cardoso W.V., Lu J. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2011, 45:287-294.
5. Dickson R.P., Erb-Downward J.R., Freeman C.M., Walker N., Scales B.S., Beck J.M., Martinez F.J., Curtis J.L., Lama V.N., Huffnagle G.B. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLoS One 2014, 9:e97214.
6. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9:102-114.
7. Flaherty K.R., Thwaite E.L., Kazerooni E.A., Gross B.H., Toews G.B., Colby T.V., Travis W.D., Mumford J.A., Murray S., Flint A., Lynch J.P., Martinez F.J. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003, 58:143-148.
8. Flaherty K.R., King T.E., Raghu G., Lynch J.P., Colby T.V., Travis W.D., Gross B.H., Kazerooni E.A., Toews G.B., Long Q., Murray S., Lama V.N., Gay S.E., Martinez F.J. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am. J. Respir. Crit. Care Med. 2004, 170:904-910.
9. Grutters J.C., du Bois R.M. Genetics of fibrosing lung diseases. Eur. Respir. J. 2005, 25:915-927.
10. Hwang H.W., Mendell J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 2006, 94:776-780.
11. Kendziorski C., Irizarry R.A., Chen K.S., Haag J.D., Gould M.N. On the utility of pooling biological samples in microarray experiments. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4252-4257.
12. Kinder B.W., Brown K.K., Schwarz M.I., Ix J.H., Kervitsky A., King T.E. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008, 133:226-232.
13. Koppers-Lalic D., Hogenboom M.M., Middeldorp J.M., Pegtel D.M. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv. Drug Deliv. Rev. 2013, 65:348-356.
14. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
15. Ley B., Collard H.R., King T.E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011, 183:431-440.
16. Li X., Zhang H., Soledad-Conrad V., Zhuang J., Uhal B.D. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 284:L501-L507.
17. Li Y., Jiang D., Liang J., Meltzer E.B., Gray A., Miura R., Wogensen L., Yamaguchi Y., Noble P.W. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J. Exp. Med. 2011, 208:1459-1471.
18. Li P., Li J., Chen T., Wang H., Chu H., Chang J., Zang W., Wang Y., Ma Y., Du Y., Zhao G., Zhang G. Expression analysis of serum microRNAs in idiopathic pulmonary fibrosis. Int. J. Mol. Med. 2014, 33:1554-1562.
19. Lino Cardenas C.L., Henaoui I.S., Courcot E., Roderburg C., Cauffiez C., Aubert S., Copin M.C., Wallaert B., Glowacki F., Dewaeles E., Milosevic J., Maurizio J., Tedrow J., Marcet B., Lo-Guidice J.M., Kaminski N., Barbry P., Luedde T., Perrais M., Mari B., Pottier N. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet. 2013, 9:e1003291.
20. Liu G., Friggeri A., Yang Y., Milosevic J., Ding Q., Thannickal V.J., Kaminski N., Abraham E. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 2010, 207:1589-1597.
21. Lusa L., Cappelletti V., Gariboldi M., Ferrario C., De Cecco L., Reid J.F., Toffanin S., Gallus G., McShane L.M., Daidone M.G., Pierotti M.A. Questioning the utility of pooling samples in microarray experiments with cell lines. Int. J. Biol. Markers 2006, 21:67-73.
22. Molina-Molina M., Xaubet A., Li X., Abdul-Hafez A., Friderici K., Jernigan K., Fu W., Ding Q., Pereda J., Serrano-Mollar A., Casanova A., Rodriguez-Becerra E., Morell F., Ancochea J., Picado C., Uhal B.D. Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur. Respir. J. 2008, 32:1004-1008.
23. Momen-Heravi F., Bala S., Bukong T., Szabo G. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine 2014, 10:1517-1527.
24. Monleon I., Martinez-Lorenzo M.J., Monteagudo L., Lasierra P., Taules M., Iturralde M., Pineiro A., Larrad L., Alava M.A., Naval J., Anel A. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J. Immunol. 2001, 167:6736-6744.
25. Navaratnam V., Fleming K.M., West J., Smith C.J., Jenkins R.G., Fogarty A., Hubbard R.B. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011, 66:462-467.
26. Pandit K.V., Milosevic J., Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl. Res. 2011, 157:191-199.
27. Pantelidis P., Fanning G.C., Wells A.U., Welsh K.I., Du Bois R.M. Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2001, 163:1432-1436.
28. Papadopoulos G.L., Alexiou P., Maragkakis M., Reczko M., Hatzigeorgiou A.G. DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics 2009, 25:1991-1993.
29. Pottier N., Maurin T., Chevalier B., Puissegur M.P., Lebrigand K., Robbe-Sermesant K., Bertero T., Lino Cardenas C.L., Courcot E., Rios G., Fourre S., Lo-Guidice J.M., Marcet B., Cardinaud B., Barbry P., Mari B. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoS One 2009, 4:e6718.
30. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur. Respir. J. 2011, 37:743-746.
31. Reinsbach S., Nazarov P.V., Philippidou D., Schmitt M., Wienecke-Baldacchino A., Muller A., Vallar L., Behrmann I., Kreis S. Dynamic regulation of microRNA expression following interferon-gamma-induced gene transcription. RNA Biol. 2012, 9:978-989.
32. Richards T.J., Kaminski N., Baribaud F., Flavin S., Brodmerkel C., Horowitz D., Li K., Choi J., Vuga L.J., Lindell K.O., Klesen M., Zhang Y., Gibson K.F. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012, 185:67-76.
33. Richeldi L. Idiopathic pulmonary fibrosis: current challenges and future perspectives. Eur. Respir. Rev. 2013, 22:103-105.
34. Scian M.J., Maluf D.G., David K.G., Archer K.J., Suh J.L., Wolen A.R., Mba M.U., Massey H.D., King A.L., Gehr T., Cotterell A., Posner M., Mas V. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am. J. Transplant. 2011, 11:2110-2122.
35. Selman M., Pardo A., Barrera L., Estrada A., Watson S.R., Wilson K., Aziz N., Kaminski N., Zlotnik A. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2006, 173:188-198.
36. Selman M., Carrillo G., Estrada A., Mejia M., Becerril C., Cisneros J., Gaxiola M., Perez-Padilla R., Navarro C., Richards T., Dauber J., King T.E., Pardo A., Kaminski N. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007, 2:e482.
37. Sumikawa H., Johkoh T., Colby T.V., Ichikado K., Suga M., Taniguchi H., Kondoh Y., Ogura T., Arakawa H., Fujimoto K., Inoue A., Mihara N., Honda O., Tomiyama N., Nakamura H., Muller N.L. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am. J. Respir. Crit. Care Med. 2008, 177:433-439.
38. Wang X.F., Cai H.R. Progress in idiopathic pulmonary fibrosis and microRNAs. Zhonghua Jie He He Hu Xi Za Zhi 2012, 35:442-446.
39. Williams A.H., Liu N., van Rooij E., Olson E.N. MicroRNA control of muscle development and disease. Curr. Opin. Cell Biol. 2009, 21:461-469.
40. Xaubet A., Marin-Arguedas A., Lario S., Ancochea J., Morell F., Ruiz-Manzano J., Rodriguez-Becerra E., Rodriguez-Arias J.M., Inigo P., Sanz S., Campistol J.M., Mullol J., Picado C. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003, 168:431-435.
41. Yokoyama A., Kohno N., Hamada H., Sakatani M., Ueda E., Kondo K., Hirasawa Y., Hiwada K. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998, 158:1680-1684.